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Campylobacter jejuni infections are progressively increasing worldwide. Probiotic treatment might 
open novel therapeutic or even prophylactic approaches to combat campylobacteriosis. In the present 
study secondary abiotic mice were generated by broad-spectrum antibiotic treatment and perorally 
reassociated with a commensal murine Lactobacillus johnsonii strain either 14 days before (i.e. 
prophylactic regimen) or 7 days after (i.e. therapeutic regimen) peroral C. jejuni strain 81–176 infection. 
Following peroral reassociation both C. jejuni and L. johnsonii were able to stably colonize the murine 
intestinal tract. Neither therapeutic nor prophylactic L. johnsonii application, however, could decrease 
intestinal C. jejuni burdens. Notably, C. jejuni induced colonic apoptosis could be ameliorated by 
prophylactic L. johnsonii treatment, whereas co-administration of L. johnsonii impacted adaptive (i.e. T 
and B lymphocytes, regulatory T cells), but not innate (i.e. macrophages and monocytes) immune cell 
responses in the intestinal tract. Strikingly, C. jejuni induced intestinal, extra-intestinal and systemic 
secretion of pro-inflammatory mediators (such as IL-6, MCP-1, TNF and nitric oxide) could be alleviated 
by peroral L. johnsonii challenge. In conclusion, immunomodulatory probiotic species might offer 
valuable strategies for prophylaxis and/or treatment of C. jejuni induced intestinal, extra-intestinal as 
well as systemic pro-inflammatory immune responses in vivo.
Human Campylobacter jejuni infections are progressively rising worldwide1, 2. Whereas C. jejuni act as commensal 
bacteria within the intestinal tract of wild and domestic animals, humans acquire C. jejuni usually by consump-
tion of contaminated products derived from livestock animals or contaminated surface water via the peroral 
route and present with clinical symptoms of varying degree3–6. Whereas some patients suffer from rather mild 
malaise, others present with gastroenteritis ranging from watery diarrhea to severe ulcerative colitis with inflam-
matory, bloody diarrhea7. Whereas in the vast majority of cases disease resolves spontaneously, post-infectious 
sequelae including peripheral neuropathies such as Guillain-Barré and Miller-Fisher syndromes and reactive 
arthritis might develop with a latency of weeks to months8–10. Due to the scarcity of appropriate in vivo models, 
our understanding of the molecular mechanisms underlying Campylobacter-host interactions has been hampered 
for a long time6, 11. In general, mice are highly convenient for studies of bacterial pathogenicity and pathogen-host 
interactions. Conventionally colonized mice, however, are protected from C. jejuni infection due to their host 
specific microbiota composition mediating physiological colonization resistance6, 12. Our group showed pre-
viously that C. jejuni infection could be facilitated by modification of the murine intestinal microbiota6, 12, 13. 
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Physiological colonization resistance could be overcome upon virtual eradication of the intestinal microbiota by 
broad-spectrum antibiotic treatment. These secondary abiotic mice could be stably infected with the pathogen 
and exhibited key features of human campylobacteriosis including apoptosis and pro-inflammatory immune 
responses in the large intestines12. Hence, secondary abiotic mice are well-suited to unravel the triangle relation-
ship between intestinal pathogens, commensals and the host immune system in vivo14. These findings suggest that 
microorganisms in the gut microbiota of our laboratory mice might contribute to colonization resistance against 
C. jejuni, thus providing health benefits to the host similar to probiotics15.
It is well-established that modulation of the intestinal microbiota composition by probiotic microbes is a 
promising strategy to prevent pathogenic colonization and subsequent infection in susceptible hosts15, 16. The 
reduction of the C. jejuni loads in poultry and other livestock animals is a highly preventive measure to prevent 
campylobacteriosis in humans. The molecular mechanisms inhibiting C. jejuni colonization are in the actual focus 
of research. In this context the extraordinary colonization resistance displayed by our conventional mice against 
C. jejuni raises intensive scientific interest. The murine intestinal microbiota is dominated by Gram-positive lac-
tobacilli belonging to the Lacobacillaceae of the Lactobacillales within the Bacilli class of the Firmicutes16, 17. The 
genus is the most diverse amongst the lactic acid bacteria, and a variety of probiotic lactobacilli including L. aci-
dophilus/L. johnsonii, L. casei, L. rhamnosus, L. gasseri, and closely related Bifidobacterium lactis have been shown 
to inhibit virulence of enteropathogenic bacteria including Campylobacter, Salmonella, Shigella, enterotoxigenic 
E. coli or Vibrio cholerae to intestinal cells18–22. In particular for C. jeuni it has been conclusively demonstrated that 
L. gasseri SBT2055 inhibits invasion of epithelial cells by co-aggregation in vitro and counteracts pathogenic col-
onization in chicken23, 24. Furthermore, production of organic acids (mainly lactic acid) by probiotic lactobacilli 
exerts killing of C. jejuni in vitro and is efficiently reducing C. jejuni concentrations in vivo as shown in poultry25. 
Whereas Lactobacillus spp. isolated from probiotic formulations were highly effective in mediating colonization 
resistance against C. jejuni in mice26, bacteriocin producing L. salivarius reduced C. jejuni loads in the chicken 
intestinal tract27.
Given that distinct species in the dense Lactobacillus population in mice might be involved in mediating col-
onization resistance against C. jejuni, we isolated a commensal Lactobacillus johnsonii strain from murine fecal 
samples (see methods) and confirmed its antimicrobial activity against C. jejuni by using co-cultivation assays 
in vitro (Bachelor thesis Ulrike Escher, 2014 Beuth Hochschule, Berlin, Germany). The inhibition of C. jejuni 
growth by L. johnsonii was mediated via production of organic acids, as demonstrated by the loss of the antimi-
crobial activity against C. jejuni by neutralization of the growth media with alkalizing agents. Notably L. johnsonii 
(formerly termed L. acidophilus) constitutes a common commensal of the murine intestinal microbiota28. Given 
its scientifically confirmed probiotic potential, several L. johnsonii strains are used worldwide in probiotic prod-
ucts29. Most importantly, L. johnsonii inhibits the growth of C. jejuni in vitro as already known for decades30.
In the present study we investigated the potential probiotic/beneficial effects of L. johnsonii in murine campy-
lobacteriosis by prophylactic and therapeutic treatment of C. jejuni infected secondary abiotic mice which were 
generated by antibiotic treatment. Results obtained by analysis of the resulting secondary abiotic animals revealed 
that prophylactic or therapeutic treatment of mice with L. johnsonii did not lower intestinal C. jejuni colonization, 
but significantly suppressed intestinal and systemic pro-inflammatory and enhanced anti-inflammatory immune 
responses.
Results
Intestinal colonization capacities of L. johnsonii and/or C. jejuni strain 81–176 in perorally reas-
sociated secondary abiotic mice. In the present study we investigated the potential of a murine com-
mensal intestinal L. johnsonii strain to reduce intestinal pathogenic burdens and to alleviate pro-inflammatory 
immune responses upon C. jejuni infection in vivo. In order to overcome physiological colonization resistance 
exerted by the conventional murine microbiota and to assure subsequent stable intestinal bacterial colonization12, 
we subjected conventionally raised and housed mice to broad-spectrum antibiotic treatment for eight weeks. 
Consequently, the murine intestinal microbiota was virtually depleted. These generated secondary abiotic mice 
were then perorally challenged with 108 colony forming units (CFU) of a L. johnsonii strain, that had initially 
been isolated from the commensal intestinal microbiota of a healthy mouse, by gavage either 14 days before (i.e. 
prophylactic regimen) or 7 days after (i.e. therapeutic regimen) peroral C. jejuni strain 81–176 infection (path-
ogenic loads of 108 CFU). At day 28 and day 21 following initial L. johnsonii and C. jejuni reassociation, respec-
tively, mice from bacterial in vivo competition experiments were compared to mono-associated and naive mice. 
Following peroral challenge, either bacterial strain was able to stably colonize the murine intestinal tract with 
high median loads of approximately 108 to 109 CFU per gram feces (Fig. 1). Within 14 days following L. johnsonii 
coassociation of C. jejuni infected mice, fecal pathogenic burdens could be lowered by less than 0.5 order of mag-
nitude (p < 0.05; Fig. 1d). Overall, both C. jejuni and L. johnsonii stably colonized the intestinal tract of secondary 
abiotic mice at comparable loads. Neither therapeutic nor prophylactic L. johnsonii application, however, was able 
to decrease intestinal pathogenic burdens in a biologically relevant fashion (Fig. 1c,d).
Large intestinal apoptosis following reassociation of secondary abiotic mice with C. jejuni and/
or L. johnsonii. Since reassociation of secondary abiotic mice with C. jejuni and/or L. johnsonii did not affect 
mice macroscopically (i.e. clinically; not shown), we next investigated potential microscopic sequelae of respective 
bacterial challenges. Apoptosis is a well-established marker for histopathological grading of intestinal inflamma-
tion and a key feature of campylobacteriosis12. We therefore quantitatively assessed caspase3 positive cell numbers 
in colonic epithelia applying in situ immunohistochemistry. C. jejuni infected mice exhibited increased numbers 
of apoptotic cells in their large intestines as compared to naive and L. johnsonii mono-associated mice (p < 0.005–
0.001; Fig. 2a; Supplemental Fig. S1). Prophylactic administration of L. johnsonii, however, was associated with 
approximately 50% lower apoptotic colonic epithelial cell numbers as compared to C. jejuni mono-associated 
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mice (p < 0.05; Fig. 2a; Supplemental Fig. S1), whereas a trend towards less apoptosis could also be observed in 
the L. johnsonii treatment group (n.s.; Fig. 2a; Supplemental Fig. S1). Notably, L. johnsonii application alone did 
not induce colonic apoptosis (n.s. vs naive controls; Fig. 2a; Supplemental Fig. S1). Reassociation of gnotobiotic 
mice with C. jejuni and/or L. johnsonii was further accompanied by increases in colonic numbers of Ki67 positive 
cells indicative for cell proliferation and regeneration counteracting potential C. jejuni induced epithelial cell 
damage (p < 0.005–0.001; Fig. 2b; Supplemental Fig. S1). Hence, C. jejuni induced colonic apoptosis could be 
ameliorated by pre-treatment with L. johnsonii.
Large intestinal innate and adaptive immune cell responses upon reassociation of secondary 
abiotic mice with C. jejuni and/or L. johnsonii. Recruitment of pro-inflammatory immune cells to the 
site of infection is a characteristic feature of intestinal inflammation including campylobacteriosis12. We therefore 
quantitatively determined distinct innate as well as adaptive immune cell subsets in large intestinal ex vivo biop-
sies by in situ immunohistochemistry. Peroral C. jejuni infection, but not L. johnsonii application alone resulted in 
increased colonic numbers of T and B lymphocytes, regulatory T cells (Treg) as well as macrophages and mono-
cytes (p < 0.001; Fig. 3; Supplemental Fig. S1). Colonic T lymphocyte numbers, however, decreased (p < 0.005), 
whereas conversely, Treg counts increased (p < 0.05–0.001) in bacterial competition experiments as compared to 
mice subjected to C. jejuni alone, irrespective whether L. johnsonii was applied prophylactically or therapeutically 
(Fig. 3a,b; Supplemental Fig. S1). Furthermore therapeutic, but not prophylactic L. johnsonii treatment of C. jejuni 
infected mice resulted in decreased colonic B lymphocyte numbers (p < 0.001; Fig. 3c; Supplemental Fig. S1). 
Notably, large intestinal counts of macrophages and monocytes were not affected by L. johnsonii co-association of 
C. jejuni infected animals (n.s.; Fig. 3d; Supplemental Fig. S1).
Intestinal cytokine responses upon reassociation of secondary abiotic mice with C. jejuni and/
or L. johnsonii. We further measured pro- and anti-inflammatory cytokine secretion in distinct intestinal 
compartments generated in bacterial in vivo competition experiments. In colonic ex vivo biopsies, IL-6 and 
MCP-1 concentrations increased following mono-association of secondary abiotic mice with L. johnsonii or C. 
jejuni, which was also true for prophylactically with L. johnsonii treated C. jejuni infected animals (p < 0.05–
0.001; Fig. 4a,b). Notably, colonic secretion of respective pro-inflammatory cytokines was similar in naive and C. 
jejuni associated mice that were therapeutically treated with L. johnsonii (n.s.; Fig. 4a,b). Furthermore, colonic 
Figure 1. Kinetics of intestinal L. johnsonii and/or C. jejuni strain 81–176 loads in perorally reassociated 
secondary abiotic mice. Secondary abiotic mice were generated by broad-spectrum antibiotic treatment and 
perorally reassociated with (a) L. johnsonii (Lac; white squares) on day (d) −14, (b) C. jejuni strain 81–176 (Cj; 
black circles) on d0, (c) L. johnsonii on day −14 and C. jejuni strain 81–176 on d0, or (d) C. jejuni strain 81–176 
(d-7) and L. johnsonii on d0 as described in methods. Bacterial colonization densities were assessed in fecal 
samples (CFU/g, colony forming units per gram) over time upon reassociation as indicated by culture. Medians 
(black bars) and levels of significance (p-value) determined by Mann-Whitney U test are indicated. Numbers 
of analyzed mice are given in parentheses. Data were pooled from three independent experiments. N.d.: not 
determined.
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levels of the anti-inflammatory cytokine IL-10 increased upon C. jejuni infection, except for therapeutically with 
L. johnsonii treated animals (p < 0.05; Fig. 4c).
Even though C. jejuni has been known to primarily affect the large intestines11, we expanded our cytokine 
measurements to the small intestinal tract. Remarkably, C. jejuni induced increases in ileal TNF and nitric oxide 
(NO) secretion could be dampened to naive levels by both prophylactic and therapeutic L. johnsonii administra-
tion (p < 0.05 and p < 0.005, respectively; Fig. 4d,e). Like in the colon, IL-10 concentrations increased in the distal 
small intestinal tract upon C. jejuni mono-association as well as in C. jejuni infected mice that were prophylacti-
cally treated with L. johnsonii (p < 0.01 and p < 0.05, respectively; Fig. 4f).
Furthermore, NO levels were increased in mesenteric lymph nodes (MLN) of C. jejuni infected mice 
(p < 0.005), but could be reduced to basal (naive) levels by L. johnsonii co-administration (p < 0.05–0.001; 
Fig. 5a). Upon bacterial reassociation of either regimen, elevated IL-10 concentrations could be measured in 
MLN of secondary abiotic mice (p < 0.05–0.005; Fig. 5b).
Hence, C. jejuni induced increases in intestinal pro-inflammatory cytokine secretion could be alleviated by 
peroral L. johnsonii challenge. Notably, respective beneficial immunomodulatory effects were not restricted to 
the large intestinal tract.
Extra-intestinal cytokine responses upon reassociation of secondary abiotic mice with C. jejuni 
and/or L. johnsonii. We next investigated whether potential immunomodulatory properties of L. johnso-
nii were restricted to the intestinal tract or could additionally even be observed in an extra-intestinal compart-
ment such as the liver. TNF concentrations increased multifold in livers upon C. jejuni infection (p < 0.01–0.001; 
Fig. 6a). These increases, however, could be reduced by prophylactic as well as therapeutic co-administration of 
L. johnsonii (p < 0.005; Fig. 6a), that was most pronounced in the latter group. Moreover, increased hepatic IL-6 
secretion could be determined upon C. jejuni infection (p < 0.05; Fig. 6b), except for with L. johnsonii prophy-
lactically treated mice. Furthermore, IL-10 concentrations were elevated in livers following C. jejuni mono-, but 
not co-association with L. johnsonii (Fig. 6c). Hence, alleviation of C. jejuni induced pro-inflammatory immune 
responses by L. johnsonii was not restricted to the intestinal tract.
Systemic cytokine responses upon reassociation of secondary abiotic mice with C. jejuni and/
or L. johnsonii. Given the beneficial effects of L. johnsonii observed in extra-intestinal tissue sites of C. jejuni 
infected mice we next addressed whether respective immunomodulatory “probiotic” properties could also be 
observed systemically. We therefore measured cytokine secretion in spleen and serum samples derived from 
bacterial in vivo competition experiments. Following bacterial reassociation, splenic TNF, IFN-γ, IL-6 as well as 
IL-10 concentrations increased multifold (p < 0.01–0.001; Fig. 7a,b,d,e). Notably, C. jejuni induced TNF levels 
could be lowered by prophylactic and therapeutic coassociation with L. johnsonii (p < 0.05 and 0.01, respectively; 
Figure 2. Apoptotic and proliferating cells in the colonic epithelium of C. jejuni strain 81–176 and/or L. 
johnsonii associated secondary abiotic mice. Secondary abiotic mice were perorally infected with C. jejuni strain 
81–176 (Cj) and associated with L. johnsonii (Lac) either 14 days before (prophylactic regimen, Proph; white 
squares) or 7 days thereafter (therapeutic regimen, Therap; black squares) and compared to mono-associated 
mice (+Lac, white circles; +Cj, black circles). The average number of colonic (a) apoptotic cells (positive 
for caspase-3, Casp3) and (b) proliferating cells (positive for Ki67) from six high power fields (HPF, 400x 
magnification) per animal was determined microscopically in immunohistochemically stained colonic paraffin 
sections at days 21 or 28 following initial C. jejuni or L. johnsonii infection, respectively. Naive mice (black 
diamonds) served as uninfected controls. Medians (black bars), levels of significance (p-values) determined 
by one-way ANOVA test followed by Tukey post-correction test for multiple comparisons and numbers of 
analyzed animals (in parentheses) are indicated. Data were pooled from three independent experiments.
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Fig. 7a). In addition, neither L. johnsonii mono-association nor prophylactic co-association of C. jejuni infected 
mice was associated with increased splenic MCP-1 levels (n.s. vs naive mice; Fig. 7c). Furthermore, increased 
TNF serum concentrations could be measured upon C. jejuni infection alone and following prophylactic, but not 
therapeutic L. johnsonii co-association of C. jejuni infected mice (Fig. 8a). Whereas bacterial reassociation was 
accompanied by increased MCP-1 concentrations in serum (p < 0.005–0.001; Fig. 8b), C. jejuni induced increases 
in serum MCP-1 levels could be lowered by therapeutic L. johnsonii treatment (p < 0.05; Fig. 8b). In line with this, 
prophylactic as well as therapeutic L. johnsonii co-association reduced C. jejuni induced increases in serum IL-6 
levels to basal levels (p < 0.01 and p < 0.001, respectively; Fig. 8c). Notably, neither viable L. johnsonii nor C. jejuni 
could be isolated from extra-intestinal and systemic compartments including liver, spleen and blood at necropsy 
(not shown). Hence, L. johnsonii administration ameliorated not only intestinal and extra-intestinal, but also 
systemic C. jejuni induced pro-inflammatory cytokine responses.
Figure 3. Colonic immune cell responses in C. jejuni strain 81–176 and/or L. johnsonii reassociated secondary 
abiotic mice. Secondary abiotic mice were perorally infected with C. jejuni strain 81–176 (Cj) and associated 
with L. johnsonii (Lac) either 14 days before (prophylactic regimen, Proph; white squares) or 7 days thereafter 
(therapeutic regimen, Therap; black squares) and compared to mono-associated mice (+Lac, white circles; +Cj, 
black circles). The average number of colonic (a) T lymphocytes (positive for CD3), (b) regulatory T cells (Treg; 
positive for FOXP3), (c) B lymphocytes (positive for B220), and (d) macrophages and monocytes (positive 
for F4/80) from six high power fields (HPF, 400x magnification) per animal was determined microscopically 
in immunohistochemically stained colonic paraffin sections at days 21 or 28 following initial C. jejuni or L. 
johnsonii infection, respectively. Naive mice (black diamonds) served as uninfected controls. Medians (black 
bars), levels of significance (p-values) determined by one-way ANOVA test followed by Tukey post-correction 
test for multiple comparisons and numbers of analyzed animals (in parentheses) are indicated. Data were 
pooled from three independent experiments.
www.nature.com/scientificreports/
6Scientific RepoRts | 7: 2138  | DOI:10.1038/s41598-017-02436-2
Discussion
Probiotics are effective in the treatment of gastrointestinal diseases as supported by a multitude of scientific inves-
tigations including clinical studies31. Proposed mechanisms of beneficial probiotic action include modification 
of the intestinal microbiota32, enhancement of colonization resistance26, support of intestinal barrier functions33 
as well as modulation of innate and adaptive immunity34. In case of campylobacteriosis, probiotics (in particular 
lactobacilli) have been shown to co-aggregate with C. jejuni thus reducing the adhesion to and invasion of the 
intestinal epithelial cell layers and to suppress motility which is essential for pathogenicity24, 35. The modes of 
actions of the corresponding probiotic formulations have been examined for decades. For instance, adminis-
tration of heat killed bacteria of the closely related L. acidophilus reduced translocation of C. jejuni in infected 
isolator-raised germfree mice36.
Given that L. johnsonii and its relative L. acidophilus have been shown to produce several antimicrobial mol-
ecules including bacteriocins and peroxide37, we addressed in in vivo bacterial competition experiments shown 
here, whether pathogenic loads could be lowered upon L. johnsonii application before and/or after C. jejuni infec-
tion of secondary abiotic mice. Both probiotic and pathogenic strains could stably colonize the gastrointestinal 
tract at high loads upon peroral challenge. Unfortunately, neither therapeutic nor prophylactic L. johnsonii appli-
cation could decrease intestinal C. jejuni burdens in a biologically relevant fashion. In a previous in vivo study 
applying isolator-raised germfree mice that had been reconstituted with a complex human microbiota, a com-
plete eradication of C. jejuni from the small and large intestines could be observed upon pretreatment of human 
microbiota-associated mice with a probiotic mix of L. acidophilus, L. reuteri and Bifidobacterium infantis26. One 
needs to take into consideration, however, that the observed contrasting pathogen-eradicative outcomes could 
most likely not only be explained by the quantitative and qualitative differences in the used probiotic strains, but 
also by substantially different immunological features of the applied mouse models. Due to the lacking contact to 
any bacterial ligands and subsequent absence of immunological differentiation and stimulation, isolator-raised 
germfree mice exhibit only poorly-developed intestinal lymphatic tissues38, 39, and need thus to be regarded as 
highly immunocompromized and inappropriate for dissecting commensal intestinal-pathogen-host interac-
tions. The secondary abiotic mice used in our study, however, were born, reared and maintained under conven-
tional conditions and exhibited a fully developed innate and adaptive immune system. Notably, recolonization of 
Figure 4. Intesinal secretion of pro- and anti-inflammatory mediators in C. jejuni strain 81–176 and/or 
L. johnsonii reassociated secondary abiotic mice. Secondary abiotic mice were perorally infected with C. 
jejuni strain 81–176 (Cj) and associated with L. johnsonii (Lac) either 14 days before (prophylactic regimen, 
Proph; white squares) or 7 days thereafter (therapeutic regimen, Therap; black squares) and compared to 
mono-associated mice (+Lac, white circles; +Cj, black circles). Colonic (a) IL-6, (b) MCP-1 and (c) IL-10 
concentrations as well as ileal (d) TNF, (e) nitric oxide and (f) IL-10 secretion were determined in ex vivo 
biopsies derived at days 21 or 28 following initial C. jejuni or L. johnsonii infection, respectively. Naive (N) 
mice (black diamonds) served as uninfected controls. Medians (black bars), levels of significance (p-value) 
determined by one-way ANOVA test followed by Tukey post-correction test for multiple comparisons and 
numbers of analyzed animals (in parentheses) are indicated. Data were pooled from three independent 
experiments.
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secondary abiotic mice with a single probiotic strains might not be sufficient to reconstitute the complex physio-
logical prerequisites (i.e. colonization resistance) for effective competition with C. jejuni for nutrients and niches. 
Thus, rather a combination of several beneficial microbes instead of one single probiotic strain would be a more 
promising strategy to protect from or combat established enteropathogenic infections.
Whereas in our study re-colonized mice were not clinically/macroscopically compromized, C. jejuni infec-
tion induced colonic apoptosis and inflammation. Notably, L. johnsonii colonization alone did not induce 
apoptotic, but promoted proliferative/regenerative colonic epithelial responses that might counteract potential 
inflammation-attributed cell damage. Most importantly, the C. jejuni induced disease state could be amelio-
rated by treatment with L. johnsonii, which impacted apoptosis and adaptive immune responses upon C. jejuni 
infection. Again, L. johnsonii alone did not lead to an influx of innate or adaptive immune cells into the colonic 
mucosa and lamina propria. Furthermore, increases in intestinal pro-inflammatory mediators (including IL-6, 
NO and TNF) induced by C. jejuni infection could be alleviated by peroral L. johnsonii co-administration. 
Notably, respective beneficial immunomodulatory effects were not restricted to the large intestinal tract, but 
could also be observed in the ileum. As compared to uninfected control mice, L. johnsonii application alone fur-
ther resulted in enhanced IL-10 secretion in intestinal as well as systemic compartments as shown from ex vivo 
biopsies taken from MLN and spleen, respectively. Our in vivo data are further supported by results from in vitro 
studies. Tsuda and colleagues reported, for instance, that stimulation of intestinal lymphocytes (derived from 
MLN of isolator-raised germfree mice) with a mix of three defined and inactivated L. johnsonii strains induced 
IL-10 production and regulated excessive antigen-specific cytokine responses via antigen presenting cells40. In 
line with this, stimulation of peritoneal macrophages with L. johnsonii also resulted in enhanced IL-10 secretion41. 
In weanling as well as malnourished aged mice, L. johnsonii challenge further enhanced intestinal IgA secretion, 
thus constituting recovery and/or modulation of accelerated immune responses within the intestinal tract42, 43.
In our study L. johnsonii administration did not only ameliorate intestinal, but also extra-intestinal such as 
hepatic, and most strikingly, systemic C. jejuni induced pro-inflammatory cytokine responses. In support, a study 
applying a murine leukemia model revealed that peroral restoration of commensal Lactobacillus spp. (that were 
reduced upon disease-mediated dysbiosis) resulted in decreased levels of pro-inflammatory cytokines including 
IL-6 and MCP-1 in muscular as well as serum samples44. Given that the efficacy of L. johnsonii as therapeutic 
and/or preventive measure directed against enteric diseases including infections is supported by solid data from 
experimental in vitro and in vivo investigations as well as clinical studies37, it has been included in probiotic prod-
ucts distributed worldwide (Nestlé LC1).
In conclusion, even though neither susceptibility to C. jejuni infection nor pathogenic burdens upon intes-
tinal establishment were influenced by L. johnsonii co-administration, the anti-inflammatory properties of this 
single probiotic species that became overt in intestinal, extra-intestinal and, remarkably, systemic compartments 
of C. jejuni infected mice qualifies L. johnsonii at least as adjunct immunomodulatory application. It is rather 
a well-orchestrated interplay of mucosal immunity and the intestinal intraluminal milieu determined by the 
concert of the complex microbiota plus beneficial probiotic strains that is required to successfully combat and/or 
Figure 5. Secretion of pro- and anti-inflammatory mediators in mesenteric lymph nodes of C. jejuni strain 
81–176 and/or L. johnsonii reassociated secondary abiotic mice. Secondary abiotic mice were perorally infected 
with C. jejuni strain 81–176 (Cj) and associated with L. johnsonii (Lac) either 14 days before (prophylactic 
regimen, Proph; white squares) or 7 days thereafter (therapeutic regimen, Therap; black squares) and compared 
to mono-associated mice (+Lac, white circles; +Cj, black circles). (a) Nitric oxide and (b) IL-10 concentrations 
were determined in ex vivo biopsies derived from mesenteric lymph nodes (MLN) at days 21 or 28 following 
initial C. jejuni or L. johnsonii infection, respectively. Naive (N) mice (black diamonds) served as uninfected 
controls. Medians (black bars), level of significance (p-value) determined by one-way ANOVA test followed 
by Tukey post-correction test for multiple comparisons and numbers of analyzed animals (in parentheses) are 
indicated. Data were pooled from three independent experiments.
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Figure 6. Secretion of pro- and anti-inflammatory mediators in livers of C. jejuni strain 81–176 and/or L. 
johnsonii reassociated secondary abiotic mice. Secondary abiotic mice were perorally infected with C. jejuni 
strain 81–176 (Cj) and associated with L. johnsonii (Lac) either 14 days before (prophylactic regimen, Proph; 
white squares) or 7 days thereafter (therapeutic regimen, Therap; black squares) and compared to mono-
associated mice (+Lac, white circles; +Cj, black circles). (a) TNF, (b) IL-6 and (c) IL-10 concentrations were 
determined in ex vivo biopsies derived from livers at days 21 or 28 following initial C. jejuni or L. johnsonii 
infection, respectively. Naive (N) mice (black diamonds) served as uninfected controls. Medians (black bars), 
levels of significance (p-value) determined by one-way ANOVA test followed by Tukey post-correction test for 
multiple comparisons and numbers of analyzed animals (in parentheses) are indicated. Data were pooled from 
three independent experiments.
Figure 7. Splenic secretion of pro- and anti-inflammatory mediators of C. jejuni strain 81–176 and/or L. 
johnsonii reassociated secondary abiotic mice. Secondary abiotic mice were perorally infected with C. jejuni 
strain 81–176 (Cj) and associated with L. johnsonii (Lac) either 14 days before (prophylactic regimen, Proph; 
white squares) or 7 days thereafter (therapeutic regimen, Therap; black squares) and compared to mono-
associated mice (+Lac, white circles; +Cj, black circles). (a) TNF, (b) INF-γ, (c) MCP-1, (d) IL-6, and (e) IL-10 
concentrations were determined in ex vivo biopsies derived from spleens at days 21 or 28 following initial C. 
jejuni or L. johnsonii infection, respectively. Naive (N) mice (black diamonds) served as uninfected controls. 
Medians (black bars), levels of significance (p-value) determined by one-way ANOVA test followed by Tukey 
post-correction test for multiple comparisons and numbers of analyzed animals (in parentheses) are indicated. 
Data were pooled from three independent experiments.
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prevent from enteropathogenic infections. Future studies are needed, however, to better understand the under-
lying mechanisms.
Material and Methods
Ethics statement. All animal experiments were conducted according to the European Guidelines for animal 
welfare (2010/63/EU) with approval of the commission for animal experiments headed by the “Landesamt für 
Gesundheit und Soziales” (LaGeSo, Berlin, registration number G0184/12). Animal welfare was monitored twice 
daily by assessment of clinical conditions including weight loss.
Generation of secondary abiotic mice. Female C57BL/6j mice were reared and housed within the same 
specific pathogen free (SPF) unit in the Forschungseinrichtungen für Experimentelle Medizin (FEM, Charité - 
University Medicine Berlin). Secondary abiotic mice were generated by quintuple antibiotic treatment for eight 
weeks starting 10 weeks of age as described before45. Mice were kept in cages including filter tops within an exper-
imental semi-barrier (accessible only with lab coat, overshoes, caps and sterile gloves) under standard conditions 
(22–24 °C room temperature, 55 ± 15% humidity, 12 h light/12 dark cycle). Mice were handled under aseptic con-
ditions and had unlimited access to autoclaved tap water and chow (food pellets; Sniff, Soest, Germany). Murine 
samples were taken at comparable time points in the morning.
Bacterial in vivo competition experiments. Three days before bacterial reassociation experiments the 
antibiotic cocktail was replaced by sterilized tap water. Mice were then perorally challenged by gavage with either 
C. jejuni strain 81–176 or with a commensal L. johnsonii strain that had initially been isolated from the intesti-
nal tract of a healthy female 3 months-old C57BL/6j wildtype mouse (respective bacterial loads of 108 CFU) as 
described previously12, 45. Briefly, single colonies of lactic acid bacteria were isolated from murine feces samples 
by cultivation of serial dilutions on MRS selective agar (Oxoid, Wesel, Germany). The capacity of the isolates to 
inhibit growth of C. jejuni was examined by co-cultivation assays with C. jejuni strain 81–176 on Columbia agar 
supplemented with 5% sheep blood (Oxoid) and in thioglycolate liquid media (Bachelor thesis Ulrike Escher, 
Beuth Hochschule, Berlin, Germany), according to standard microbial stabbing techniques for isolation of lacto-
bacilli which are inhibitory for pathogens46. The isolate that mediated the most extensive growth inhibition of C. 
jejuni strain 81–176 in both assays was further investigated. The corresponding pleomorphic Gram-positive rods 
did neither produce catalase nor oxidase and were identified as L. johnsonii by molecular analysis of the complete 
16S rRNA gene sequence.
For bacterial in vivo competition experiments, C. jejuni infected mice were either challenged with L. johnsonii 
7 days thereafter (therapeutic regimen) or 14 days before (prophylactic regimen). Naive sex and age-matched ani-
mals served as uninfected (negative) controls. Mice were continuously kept in a sterile environment (autoclaved 
food and drinking water or sterile antibiotic cocktail ad libitum) and were handled under strict aseptic conditions 
in order to prevent from contaminations.
Clinical Score. To survey clinical signs of inflammation, a standardized cumulative clinical score (maximum 
12 points), addressing the occurrence of blood in feces (0: no blood; 2: microscopic detection of blood by the 
Guajac method using Haemoccult, Beckman Coulter/PCD, Krefeld, Germany; 4: overt blood visible), diarrhea 
(0: formed feces; 2: pasty feces; 4: liquid feces), and the clinical aspect (0: normal; 2: ruffled fur, less locomotion; 4: 
isolation, severely compromized locomotion, pre-final aspect) was applied daily as described earlier47.
Figure 8. Pro-inflammatory cytokine secretion in serum of C. jejuni strain 81–176 and/or L. johnsonii 
reassociated secondary abiotic mice. Secondary abiotic mice were perorally infected with C. jejuni strain 81–176 
(Cj) and associated with L. johnsonii (Lac) either 14 days before (prophylactic regimen, Proph; white squares) or 
7 days thereafter (therapeutic regimen, Therap; black squares) and compared to mono-associated mice (+Lac, 
white circles; +Cj, black circles). (a) TNF, (b) MCP-1 and (c) IL-6 concentrations were determined in serum 
samples at days 21 or 28 following initial C. jejuni or L. johnsonii infection, respectively. Naive (N) mice (black 
diamonds) served as uninfected controls. Medians (black bars), levels of significance (p-value) determined 
by one-way ANOVA test followed by Tukey post-correction test for multiple comparisons and numbers of 
analyzed animals (in parentheses) are indicated. Data were pooled from three independent experiments.
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Sampling procedures. Mice were sacrificed 21 or 28 days following initial C. jejuni or L. johnsonii reassoci-
ation, respectively, by isofluran treatment (Abbott, Greifswald, Germany). Cardiac blood and tissue samples from 
the colon, ileum, MLN, liver and spleen were removed under sterile conditions. Intestinal samples were collected 
in parallel for microbiological and immunological analyses. Immunohistological changes were assessed in colonic 
ex vivo biopsies that had been immediately fixed in 5% formalin and embedded in paraffin. Sections (5 μm) were 
stained with distinct antibodies for in situ immunohistochemistry as described earlier14, 47.
Quantitative analysis of pathogenic and probiotic bacterial colonization and translocation. C. 
jejuni strain 81–176 and L. johnsonii were quantitated in feces over time post reassociation or upon necropsy in 
luminal samples taken from the colon, in homogenates of whole tissue ex vivo biopsies derived from spleen and 
liver (approximately 1 cm3) and in cardiac blood (approximately 1 mL). Whereas cardiac blood was analyzed by 
direct plating, feces, luminal colon contents and organ homogenates were dissolved in sterile phosphate buff-
ered saline (PBS; Gibco life technologies, Paisley, UK) and serial dilutions cultured on Karmali and Columbia 
agar supplemented with 5% sheep blood (Oxoid) for two days at 37 °C under microaerobic conditions using 
CampyGen gas packs (Oxoid) for C. jejuni detection as described earlier12. L. johnsonii loads were determined 
on Columbia agar supplemented with 5% sheep blood, Columbia-CNA agar supplemented with colistin and 
nalidixic acid (both Oxoid), and MRS agar (Oxoid) in parallel and incubated under microaerobic (in jars using 
CampGen gas packs; Oxoid) and obligate anaerobic (in jars using Anaerogen gas packs; Oxoid) conditions for 
at least two days. Bacterial species were identified according to their typical morphological appearances and 
sequencing of the 16S rRNA genes. The detection limit of viable bacteria was ≈100 CFU per g.
Immunohistochemistry. In situ immunohistochemical analysis of colonic paraffin sections was performed 
as described earlier14, 47. Primary antibodies against cleaved caspase-3 (Asp175, Cell Signaling, Boston, MA, 
USA, 1:200), Ki67 (TEC3, Dako, Glostrup, Denmark, 1:100), CD3 (#N1580, Dako, Denmark, dilution 1:10), 
FOXP3 (FJK-16s, eBioscience, San Diego, CA, USA, 1:100), B220 (eBioscience, 1:200) and F4/80 (# 14–4801, 
clone BM8, eBioscience, 1:50) were used. For each animal the average number of positively stained cells within 
at least six high power fields (HPF, 400x magnification) were determined microscopically by an independent 
blinded investigator.
Cytokine measurements in intestinal and extra-intestinal compartments. Colonic and ileal ex 
vivo biopsies were cut longitudinally and washed in PBS. MLN, spleen or strips of approximately 1 cm2 of colon, 
ileum and liver tissues were placed in 24-flat-bottom well culture plates (Nunc, Wiesbaden, Germany) contain-
ing 500 μL serum-free RPMI 1640 medium (Gibco) supplemented with penicillin (100 U/mL) and streptomy-
cin (100 µg/mL; PAA Laboratories, Cölbe, Germany). After 18 h at 37 °C, culture supernatants were tested for 
TNF, IFN-γ, MCP-1, IL-6, IL-12p70 and IL-10 by the Mouse Inflammation Cytometric Bead Assay (CBA; BD 
Biosciences, Heidelberg, Germany) on a BD FACSCanto II flow cytometer (BD Biosciences). NO was determined 
by the Griess reaction as described earlier45.
Statistical analysis. Medians, means and significance levels using appropriate tests as indicated (Mann 
Whitney U test and one-way ANOVA with Tukey’s post hoc test for multiple comparisons) were determined 
using GraphPad Prism Software v6 (La Jolla, CA, USA). Two-sided probability (p) values ≤ 0.05 were considered 
significant. Experiments were repeated twice.
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